Hematopoietic Malignancies

Hematopoietic MalignanciesHematopoietic cancers are addressed tumours of system cells. Most of them are encompassed of cells that are functionally heterogeneous with only a subdivision being responsible for tumor care. Leukemias are “liquid tumors” within the blood and are derived from the transformation of either a hematopoietic precursor within the bone marrow or a mature hematopoietic cell within the blood. Leukemias are often lymphoid or myeloid, and acute or chronic. Most hematopoietic malignancies are comprised of cells that are functionally heterogeneous with only a subset being liable for tumor maintenance.

The thorough perceptive of accumulation of genetic/epigenetic event progressions could prime to development of therapeutics that more effectively treat hematopoietic malignancies and potentially other cancers. Hematopoietic cancers (HCs) are malignancies of system cells, related to gross chromosomal abnormalities like translocations. Improvements in diagnosis and therapy, including hematopoietic somatic cell transplantation and molecularly targeted strategies, have increased patient survival.

  • Hematopoietic Cancer
  • Leukemias
  • Myeloma
  • Recurring Translocation
  • Hodgkin Lymphoma
  • Non-Hodgkin lymphoma
  • Immunotherapy
  • Lymphoma

Related Conference of Hematopoietic Malignancies

January 24-25, 2022

2nd European Congress on Hematology

Prague, Czech Republic
January 27-28, 2022

2nd World Congress on Hematology and Genetic Blood Disorders

Prague, Czech Republic
March 14-15, 2022

20th World Hematology Congress

London, UK

Hematopoietic Malignancies Conference Speakers

Recommended Sessions

Related Journals

Are you interested in